Details of the Drug Reposition

General Information of This Drug (ID: DM70BU5)

Drug Name
Thalidomide   DM70BU5
Synonyms
Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide
Therapeutic Class
Immunosuppressive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
16 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Urinary bladder neoplasm DIS7HACE N.A. Approved [1]
Testicular lymphoma DISC2M2N N.A. Approved [1]
Splenic marginal zone lymphoma DISCGTZY N.A. Approved [1]
Small intestine lymphoma DISDOS6S N.A. Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified DIS5OHQF N.A. Approved [1]
MALT lymphoma DIS1AVVE N.A. Approved [1]
Leukemia DISNAKFL N.A. Approved [1]
Hepatosplenic T-cell lymphoma DIS7KMY9 N.A. Approved [1]
Complex regional pain syndrome type 1 DISEUIQP N.A. Approved [1]
Adult T-cell leukemia/lymphoma DIS882XU N.A. Approved [1]
Advanced cancer DISAT1Z9 2A00-2F9Z Approved [1]
Prolymphocytic leukaemia DISDPPHX 2A82.1 Approved [1]
Plasma cell myeloma DIS0DFZ0 2A83.1 Approved [1]
Waldenstrom macroglobulinemia DIS9O23I 2A85.4 Approved [1]
Large granular lymphocytic leukemia DISHOPPI 2A90.1 Approved [1]
Pain DIS4RWOW MG30-MG3Z Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Indications(s)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Renal cell carcinoma DISQZ2X8 2C90 Discontinued in Phase 3 [3]
------------------------------------------------------------------------------------
3 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Discontinued in Phase 2 [4]
Oral mucositis DISS93V5 DA01.11 Discontinued in Phase 2 [5]
Rheumatoid arthritis DISTSB4J FA20 Discontinued in Phase 2 [6]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Colon cancer DISVC52G 2B90.Z Investigative [1]
------------------------------------------------------------------------------------

References

1 Thalidomide FDA Label
2 ClinicalTrials.gov (NCT04273529) The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia. U.S. National Institutes of Health.
3 Management of Incidentally Discovered Pancreatic Cysts
4 Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
5 Efficacy and Safety of Oral Alitretinoin (Toctino) in the Treatment of Patients With Cutaneous Lupus Erythematosus
6 Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer